Last $18.94 USD
Change Today -0.91 / -4.58%
Volume 548.4K
CYNO On Other Exchanges
Symbol
Exchange
CYNO is not on other exchanges.
As of 8:10 PM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

cynosure inc-a (CYNO) Snapshot

Open
$19.91
Previous Close
$19.85
Day High
$19.91
Day Low
$18.63
52 Week High
02/28/14 - $31.48
52 Week Low
07/28/14 - $18.63
Market Cap
422.7M
Average Volume 10 Days
308.7K
EPS TTM
$0.96
Shares Outstanding
22.3M
EX-Date
--
P/E TM
19.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for CYNOSURE INC-A (CYNO)

cynosure inc-a (CYNO) Related Businessweek News

View More BusinessWeek News

cynosure inc-a (CYNO) Details

Cynosure, Inc. develops, manufactures, and markets aesthetic treatment systems primarily to the dermatology, plastic surgery, and general medical markets. Its aesthetic treatment systems incorporate a range of laser and other light-based energy sources, including Alexandrite, pulse dye, Nd:YAG, Er:YAG, Erbium:glass, CO2, and diode lasers, as well as intense pulsed light devices. The company’s aesthetic treatment systems comprise Elite product line for hair removal, treatment of facial, and leg veins and pigmentations; Smartlipo product line for LaserBodySculpting for the removal of unwanted fat; Cellulaze product line for the treatment of cellulite; SmoothShapes XV product line for the temporary reduction in the appearance of cellulite; Affirm/SmartSkin product line for anti-aging applications, including treatments for wrinkles, skin texture, skin discoloration, and skin tightening; Cynergy product line for the treatment of vascular lesions; and Accolade, MedLite C6, and RevLite product lines for the removal of benign pigmented lesions, as well as multi-colored tattoos, as well as PicoSure product line for the treatment of tattoos and benign pigmented lesions. It also distributes the PinPointe FootLaser, a light-based device for the treatment of onychomycosis. The company sells its products through a direct sales force in North America, France, Spain, the United Kingdom, Germany, Korea, China, Japan, Australia, and Mexico, as well as through independent distributors in approximately 120 other countries. Cynosure, Inc. was founded in 1991 and is headquartered in Westford, Massachusetts.

576 Employees
Last Reported Date: 03/17/14
Founded in 1991

cynosure inc-a (CYNO) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $2.2M
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $1.4M
Executive Vice President of Worldwide Sales
Total Annual Compensation: $1.0M
Compensation as of Fiscal Year 2013.

cynosure inc-a (CYNO) Key Developments

Cynosure Receives Expanded FDA Clearance to Market PicoSure for Treatment of Acne Scars

Cynosure, Inc. announced that it has received FDA 510(k) clearance to market its PicoSure(TM) Picosecond Laser Workstation for the treatment of acne scars with the FOCUS lens array, the company's new disposable energy delivery system.

Cynosure, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Cynosure, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported revenues of USD 62.004 million compared to USD 40.690 million a year ago. Income from operations was USD 1.346 million compared to USD 1.988 million a year ago. Income before income taxes was USD 1.063 million compared to USD 1.663 million a year ago. Net income was USD 0.689 million compared to USD 1.239 million a year ago. Diluted net income per common share was USD 0.03 compared to USD 0.07 a year ago. Non-GAAP income from operations was USD 4.903 million compared to USD 3.440 million a year ago. Non-GAAP net income was USD 4.246 million compared to USD 2.691 million a year ago. Non-GAAP diluted net income per share was USD 0.19 compared to USD 0.16 a year ago.

Cynosure Plans Acquisitions

Cynosure, Inc. (NasdaqGS:CYNO) plans acquisitions. Michael Davin, President, Chairman and Chief Executive Officer of the company said: “We continue to focus on driving returns through focused investments and product innovation as well as accretive acquisitions that extend the depth and breadth of our product portfolio. With that I will turn the call over to Tim.” He added: “Since 2011 when we began acquiring, 2012, yes, our initiative is still to on a parallel path and drive innovation organically to the tune of a little over $20 million invested in research and development and then also utilizing our $131 million in cash that we have on the balance sheet to continue with a strategic acquisitions.”

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYNO:US $18.94 USD -0.91

CYNO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cutera Inc $10.03 USD +0.06
Lutronic Corp 20,000 KRW -250.00
PhotoMedex Inc $10.84 USD -0.43
Syneron Medical Ltd $9.88 USD -0.05
Zeltiq Aesthetics Inc $15.27 USD -0.39
View Industry Companies
 

Industry Analysis

CYNO

Industry Average

Valuation CYNO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.8x
Price/Book 1.3x
Price/Cash Flow 1,064.9x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYNOSURE INC-A, please visit www.cynosure.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.